Nano-Optogenetic Engineering of CAR T-cells for Precision Immunotherapy with Enhanced Safety

FDA-approved chimeric antigen receptor (CAR) T cell-based immunotherapy has shown curative potential in patients with hematological malignancies. However, owing to the lack of control over the location and duration of anti-tumor immune response, CAR T-cell therapy still faces significant safety chal...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Nhung Thi, Huang, Kai, Zeng, Hongxiang, Jing, Ji, Wang, Rui, Fang, Shaohai, Chen, Joyce, Liu, Xin, Huang, Zixian, You, M. James, Rao, Anjana, Huang, Yun, Han, Gang, Zhou, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678207/
https://www.ncbi.nlm.nih.gov/pubmed/34697491
http://dx.doi.org/10.1038/s41565-021-00982-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8678207/
https://www.ncbi.nlm.nih.gov/pubmed/34697491
http://dx.doi.org/10.1038/s41565-021-00982-5

Ejemplares similares